Close Menu

NEW YORK – OpGen said after the close of the market on Friday that it received a notice from Nasdaq that as of June 30 the company does not comply with a listing requirement calling for a minimum shareholder equity of $2.5 million.

As a result, the Gaithersburg, Maryland-based developer of antibiotic-resistance testing technology could face delisting action by Nasdaq. OpGen has 45 calendar days to submit a plan to regain compliance. If Nasdaq accepts the plan, it can grant the company an extension of up to 180 calendar days to become compliant with the listing requirement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.